TY - JOUR AU - Scully, M. PY - 2016 DA - 2016// TI - Thrombotic thrombocytopenic Purpura and atypical hemolytic uremic syndrome Microangiopathy in pregnancy JO - Semin Thromb Hemost VL - 42 UR - https://doi.org/10.1055/s-0036-1587683 DO - 10.1055/s-0036-1587683 ID - Scully2016 ER - TY - STD TI - Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681–96. ID - ref2 ER - TY - STD TI - Schönermarck U, Ries W, Schröppel B, Pape L, Dunaj-Kazmierowska M, Burst V, Mitzner S, Basara N, Starck M, Schmidbauer D, et al. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J. 2019;sfz066. https://doi.org/10.1093/ckj/sfz1066. ID - ref3 ER - TY - JOUR AU - Noris, M. AU - Caprioli, J. AU - Bresin, E. AU - Mossali, C. AU - Pianetti, G. AU - Gamba, S. AU - Daina, E. AU - Fenili, C. AU - Castelletti, F. AU - Sorosina, A. PY - 2010 DA - 2010// TI - Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype JO - Clin J Am Soc Nephrol VL - 5 UR - https://doi.org/10.2215/CJN.02210310 DO - 10.2215/CJN.02210310 ID - Noris2010 ER - TY - JOUR AU - Fakhouri, F. AU - Vercel, C. AU - Fremeaux-Bacchi, V. PY - 2012 DA - 2012// TI - Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy JO - Clin J Am Soc Nephrol VL - 7 UR - https://doi.org/10.2215/CJN.13121211 DO - 10.2215/CJN.13121211 ID - Fakhouri2012 ER - TY - JOUR AU - Dashe, J. S. AU - Ramin, S. M. AU - Cunningham, F. G. PY - 1998 DA - 1998// TI - The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy JO - Obstet Gynecol VL - 91 ID - Dashe1998 ER - TY - JOUR AU - Fakhouri, F. AU - Roumenina, L. AU - Provot, F. AU - Sallee, M. AU - Caillard, S. AU - Couzi, L. AU - Essig, M. AU - Ribes, D. AU - Dragon-Durey, M. A. AU - Bridoux, F. PY - 2010 DA - 2010// TI - Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations JO - J Am Soc Nephrol VL - 21 UR - https://doi.org/10.1681/ASN.2009070706 DO - 10.1681/ASN.2009070706 ID - Fakhouri2010 ER - TY - JOUR AU - Bruel, A. AU - Kavanagh, D. AU - Noris, M. AU - Delmas, Y. AU - Wong, E. K. S. AU - Bresin, E. AU - Provot, F. AU - Brocklebank, V. AU - Mele, C. AU - Remuzzi, G. PY - 2017 DA - 2017// TI - Hemolytic uremic syndrome in pregnancy and postpartum JO - Clin J Am Soc Nephrol VL - 12 UR - https://doi.org/10.2215/CJN.00280117 DO - 10.2215/CJN.00280117 ID - Bruel2017 ER - TY - JOUR AU - Gupta, M. AU - Govindappagari, S. AU - Burwick, R. M. PY - 2020 DA - 2020// TI - Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review JO - Obstet Gynecol VL - 135 UR - https://doi.org/10.1097/AOG.0000000000003554 DO - 10.1097/AOG.0000000000003554 ID - Gupta2020 ER - TY - STD TI - Vinogradova M, Kirsanova T, Shmakov R: Thrombotic microangiopathies associated with pregnancy: diagnostic and therapeutic challenges. Blood. 2018;132(Suppl 1):4810. ID - ref10 ER - TY - STD TI - EMA: EU/3/09/653. Available at: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu309653 [Accessed Jan, 2019]. 2011. UR - https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu309653 ID - ref11 ER - TY - STD TI - FDA: Eculizumab (Soliris). Available at: http://wayback.archive-it.org/7993/20170113081126/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm273089.htm [Accessed Jan, 2019]. 2011. UR - http://wayback.archive-it.org/7993/20170113081126/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm273089.htm ID - ref12 ER - TY - JOUR AU - Fakhouri, F. AU - Hourmant, M. AU - Campistol, J. M. AU - Cataland, S. R. AU - Espinosa, M. AU - Gaber, A. O. AU - Menne, J. AU - Minetti, E. E. AU - Provot, F. AU - Rondeau, E. PY - 2016 DA - 2016// TI - Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial JO - Am J Kidney Dis VL - 68 UR - https://doi.org/10.1053/j.ajkd.2015.12.034 DO - 10.1053/j.ajkd.2015.12.034 ID - Fakhouri2016 ER - TY - JOUR AU - Greenbaum, L. A. AU - Fila, M. AU - Ardissino, G. AU - Al-Akash, S. I. AU - Evans, J. AU - Henning, P. AU - Lieberman, K. V. AU - Maringhini, S. AU - Pape, L. AU - Rees, L. PY - 2016 DA - 2016// TI - Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome JO - Kidney Int VL - 89 UR - https://doi.org/10.1016/j.kint.2015.11.026 DO - 10.1016/j.kint.2015.11.026 ID - Greenbaum2016 ER - TY - JOUR AU - Legendre, C. M. AU - Licht, C. AU - Muus, P. AU - Greenbaum, L. A. AU - Babu, S. AU - Bedrosian, C. AU - Bingham, C. AU - Cohen, D. J. AU - Delmas, Y. AU - Douglas, K. PY - 2013 DA - 2013// TI - Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1208981 DO - 10.1056/NEJMoa1208981 ID - Legendre2013 ER - TY - JOUR AU - Licht, C. AU - Greenbaum, L. A. AU - Muus, P. AU - Babu, S. AU - Bedrosian, C. L. AU - Cohen, D. J. AU - Delmas, Y. AU - Douglas, K. AU - Furman, R. R. AU - Gaber, O. A. PY - 2015 DA - 2015// TI - Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies JO - Kidney Int VL - 87 UR - https://doi.org/10.1038/ki.2014.423 DO - 10.1038/ki.2014.423 ID - Licht2015 ER - TY - JOUR AU - Vilalta, R. AU - Al-Akash, S. AU - Davin, J. AU - Diaz, J. AU - Gruppo, R. AU - Hernandez, J. AU - Jungraithmayr, T. AU - Langman, C. AU - Lapeyraque, A. AU - Macher, M. PY - 2012 DA - 2012// TI - Eculizumab therapy for pediatric patients with atypical hemolytic uremic syndrome: efficacy and safety outcomes of a retrospective study JO - Haematologica VL - 97 UR - https://doi.org/10.3324/haematol.2011.060004 DO - 10.3324/haematol.2011.060004 ID - Vilalta2012 ER - TY - JOUR AU - Zuber, J. AU - Fakhouri, F. AU - Roumenina, L. T. AU - Loirat, C. AU - Fremeaux-Bacchi, V. PY - 2012 DA - 2012// TI - French study group for a HCG: use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies JO - Nat Rev Nephrol VL - 8 UR - https://doi.org/10.1038/nrneph.2012.214 DO - 10.1038/nrneph.2012.214 ID - Zuber2012 ER - TY - JOUR AU - Antonio, F. AU - Saad, J. R. AU - Wyble, A. AU - Luis, D. PY - 2016 DA - 2016// TI - Pacheco: pregnancy-associated atypical hemolytic uremic syndrome JO - Am J Perinatol VL - 6 UR - https://doi.org/10.1055/s-0036-1579539 DO - 10.1055/s-0036-1579539 ID - Antonio2016 ER - TY - JOUR AU - Demir, E. AU - Yazici, H. AU - Ozluk, Y. AU - Kilicaslan, I. AU - Turkmen, A. PY - 2016 DA - 2016// TI - Pregnant woman with atypical hemolytic uremic syndrome delivered a healthy newborn under eculizumab treatment JO - Case Rep Nephrol Dial VL - 6 UR - https://doi.org/10.1159/000454946 DO - 10.1159/000454946 ID - Demir2016 ER - TY - JOUR AU - Gately, R. AU - San, A. AU - Kurtkoti, J. AU - Parnham, A. PY - 2017 DA - 2017// TI - Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab JO - Nephrology (Carlton) VL - 22 UR - https://doi.org/10.1111/nep.12938 DO - 10.1111/nep.12938 ID - Gately2017 ER - TY - JOUR AU - Sheridan, D. AU - Yu, Z. X. AU - Zhang, Y. AU - Patel, R. AU - Sun, F. AU - Lasaro, M. A. AU - Bouchard, K. AU - Andrien, B. AU - Marozsan, A. AU - Wang, Y. PY - 2018 DA - 2018// TI - Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action JO - PLoS One VL - 13 UR - https://doi.org/10.1371/journal.pone.0195909 DO - 10.1371/journal.pone.0195909 ID - Sheridan2018 ER - TY - STD TI - FDA: Ravulizumab (ULTOMIRIS). Available at: https://alexion.com/Documents/Ultomiris_USPI.pdf [accessed Nov 2019]. 2019. UR - https://alexion.com/Documents/Ultomiris_USPI.pdf ID - ref23 ER - TY - STD TI - Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287–96. ID - ref24 ER - TY - JOUR AU - Fremeaux-Bacchi, V. AU - Miller, E. C. AU - Liszewski, M. K. AU - Strain, L. AU - Blouin, J. AU - Brown, A. L. AU - Moghal, N. AU - Kaplan, B. S. AU - Weiss, R. A. AU - Lhotta, K. PY - 2008 DA - 2008// TI - Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome JO - Blood VL - 112 UR - https://doi.org/10.1182/blood-2008-01-133702 DO - 10.1182/blood-2008-01-133702 ID - Fremeaux-Bacchi2008 ER - TY - JOUR AU - Vande Walle, J. AU - Delmas, Y. AU - Ardissino, G. AU - Wang, J. AU - Kincaid, J. F. AU - Haller, H. PY - 2017 DA - 2017// TI - Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment JO - J Nephrol VL - 30 UR - https://doi.org/10.1007/s40620-016-0288-3 DO - 10.1007/s40620-016-0288-3 ID - Vande Walle2017 ER - TY - JOUR AU - Yan, K. AU - Desai, K. AU - Gullapalli, L. AU - Druyts, E. AU - Balijepalli, C. PY - 2020 DA - 2020// TI - Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review JO - Clin Epidemiol VL - 12 UR - https://doi.org/10.2147/CLEP.S245642 DO - 10.2147/CLEP.S245642 ID - Yan2020 ER -